etoposide/karščiavimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

14 rezultatus

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Eligible patients will be treated inpatient. Patients will receive mitoxantrone 10mg/m2 administered intravenous piggyback (IVPB) in 50ml 0.9% normal saline over 15 minutes on days 1-5 and etoposide 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours on days 1-5. On

BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Hodgkin lymphoma (HL) is a lymphoid neoplasm characterized by the presence of CD30-positive Hodgkin Reed-Sternberg cells in a background of inflammatory cells. The majority of patients with HL have a good outcome with first-line chemotherapy such as ABVD (doxorubicin, bleomycin, vinblastine and

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequently fatal to the affected individual. This can occur in

Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Patients will be treated with mitoxantrone and etoposide and cytarabine. Patients will be randomly divided according to the usage of G-CSF. Subgroup with G-CSF will be treated with G-CSF after 7~10 days post-chemotherapy, when blasts will disappear from peripheral blood. Subgroup without G-CSF will

Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

5.2 AUTOLOGOUS PBSCS HARVESTING 5.2.1. PBSCs will be collected during recovery phase after the second cycle of HDAC consolidation chemotherapy. 5.2.2. For mobilization, recombinant human granulocyte- colony-stimulating factor (G-CSF, Filgrastim) will be given subcutaneously at a dose of 10 mcg/kg

Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Patients were eligible if they had early unfavorable disease or patients who presented with stage III or IV disease .Pt assigned to receive 6 cycles of Bleomycin Etoposide, Doxorubicin, Cyclophosphamide Procarbazine, Prednisone (BEACOPP) or increased dose BEACOPP. (IDB). Patient with Stage I or II

Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

There are multiple secondary objectives in this trial: - To estimate the overall event-free survival of patients treated with risk-directed therapy - To identify the plasma methotrexate (MTX) concentrations that produce maximum intracellular accumulation of active metabolites (methotrexate

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The indolent course of the low-grade B-cell lymphoma is thus characterized by multiple remissions and relapses with ever-shortening "time to progression" intervals, and by ultimately becoming refractory to treatment. In this situation of recurrences, intensive therapy including high-dose

Therapy for Children With Neuroblastoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The study will have five parts or phases. In the first part the combination of irinotecan and gefitinib will be studied. After that, patients who have responded well will have surgery to remove the tumor. This will be followed by a third part which includes about nine months of treatment with

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Background: - Treatment of pediatric sarcomas has enjoyed progress in the past 25 years for patients with localized, chemosensitive disease and prognostic factors are now available to identify subsets of patients who have very dismal prognoses; patients with primary metastatic disease, especially

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVES: I. To compare response-based therapy to standard therapy for intermediate risk Hodgkin disease. II. To determine whether involved field radiation therapy (IFRT) can be eliminated based upon early and complete response to multiagent chemotherapy. III. To determine whether the addition of

Treatment and Natural History Study of Lymphomatoid Granulomatosis

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND: - Lymphomatoid granulomatosis (LYG) is an angiocentric destructive proliferation of lymphoid cells predominantly involving the lungs, skin, kidneys, and central nervous system. - It is divided into three grades, depending on the degree of necrosis and cellular atypia. The grades of

Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVES: I. Evaluate the combination of 41.8 degrees Celsius whole body hyperthermia (WBH) and ifosfamide/carboplatin/etoposide (ICE) chemotherapy in patients with advanced sarcoma. II. Assess the efficacy of this combination of therapy. III. Assess the clinical toxicity of WBH and ICE in these

Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVES: - Determine local progression-free survival of patients with high-risk soft tissue sarcoma treated with neoadjuvant etoposide, ifosfamide, and doxorubicin with or without regional hyperthermia. - Determine the tumor response rate, local disease control rate, and overall survival in

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais